Should I Buy BMY? BMY 2026 Analysis

Should You Buy Bristol-Myers Squibb Co (BMY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

61.990

1 Day change

4.15%

52 Week Range

62.650

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now (pre-market ~58): the tape is bullish (SMA_5 > SMA_20 > SMA_200, MACD expanding) and the stock is sitting at a potential breakout zone.
Near-term trigger is earnings (today pre-market); combined with improving Wall Street tone, this creates a credible catalyst for an upside move.
Key levels: price is pressing resistance (R2 ~58.15). A clean push/hold above ~58.15 supports continuation; first meaningful support is ~55.83 pivot.
Sentiment check: options positioning is moderately bullish (put/call ratios < 1) and volume is elevated.
Main offsets to confidence: heavy insider selling trend and recent Congress-only selling argue this isn’t a “no-doubt” entry.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), consistent with an active uptrend.
Momentum: MACD histogram +0.0285 and expanding → momentum improving.
RSI (6): 76.9 → strong momentum/extended conditions (chasing risk increases near resistance).
Support/Resistance: Pivot 55.83 (important near-term support); resistance zones 57.27 (R1) and 58.15 (R2). Pre-market (~58) is testing the upper band.
Pattern-based forward view (peer candlestick analogs): modest bias to a small dip next day, mild positive next week, softer next month (not a strong tailwind for a “buy-and-forget” entry).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest put/call 0.76 and volume put/call 0.84 → skew modestly bullish (more call interest/flow than puts).
Activity: Today’s option volume 77,866, about 295.8% of the 30-day average → heightened event-driven positioning (consistent with earnings day).
Volatility: 30D IV ~25 vs HV 23.37 (slight premium). IV percentile 13.55 / IV rank 17.93 → IV is relatively low vs its own history, implying options aren’t “priced for panic.”
Trend in IV: 5D/10D IV averages (~35–36) are higher than current ~25 → IV has cooled into the event, suggesting less fear in pricing than recently.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst (QDEC 2025, reported 2026-02-05 pre-market): near-term event that can unlock a breakout if guidance/beat supports the “return to growth” narrative.
- Pipeline/Manufacturing execution: expanded OXB collaboration and commercial supply agreement for CAR-T therapies with production expected to begin in 2026.
- Product dynamics (from news context): Eliquis reported strong growth; Opdivo showing ongoing growth—supports the “stability + pipeline” thesis.
- Wall Street tone improving: multiple recent price target raises and upgrades (including UBS to Buy, BofA to Buy).

Neutral/Negative Catalysts

- Insider activity: insiders are net sellers, with selling amount up ~15,753% over the last month → notable bearish behavioral signal.
- Congress trading (last 90 days): 4 sales, 0 buys (median ~$0.8M) → influential flow is cautious.
- Patent/LOE overhang: market continues to price in future Eliquis U.S. LOE risk; this remains a structural headwind.
- Portfolio pressure points: sharp Revlimid decline referenced in news underscores ongoing erosion in legacy revenue streams.
- Competitive landscape: external analyst notes highlight competitive pressure around Camzyos category (via CYTK commentary).

Financial Performance

Latest provided quarter: 2025/Q3
- Revenue: $12.222B, +2.77% YoY (modest top-line growth).
- Net Income: $2.201B, +81.75% YoY (strong profitability improvement).
- EPS: $1.08, +80.0% YoY (earnings power improving meaningfully).
- Gross Margin: 66.1%, +18.57% YoY (material margin expansion trend).
Overall: financial trend shows stabilizing growth with sharp profitability leverage, supporting the “inexpensive + returning to growth” bull case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Trend (last ~6–8 weeks): clear shift more constructive—multiple price target raises and at least two meaningful upgrades to Buy/Overweight.
Recent highlights:
- Piper Sandler: Overweight, PT $66 (raised from $62) — sees growing visibility into a return to growth.
- UBS: Upgraded to Buy, PT $65 (from $46) — sees sector emerging from trough.
- BofA: Upgraded to Buy, PT $61 — emphasizes pipeline catalysts.
- Citi & Scotiabank: Neutral/Sector Perform, PT raised to $60 — acknowledges valuation/catalysts but stays balanced.
Wall Street pros: inexpensive/defensive pharma profile, improving pipeline visibility, catalyst-rich 2026.
Wall Street cons: LOE/patent-expiration overhang (notably Eliquis longer-term) and execution/competition risks in key franchises.

20 Analyst Rating

Wall Street analysts forecast BMY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37 USD and a high forecast of 68 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

11 Hold

1 Sell

Moderate Buy

Current: 59.520

Low

Averages

55.86

High

Current: 59.520

Low

Averages

55.86

High

Guggenheim

Buy

upgrade

$62 -> $72

AI Analysis

2026-02-06

New

Reason

Guggenheim

Price Target

$62 -> $72

AI Analysis

2026-02-06

New

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Bristol Myers to $72 from $62 and keeps a Buy rating on the shares. The firm has increased its view of the odds of success to 90% for iber/mezi from 33% previously and increased its view of the odds of success to 90% from 75% prior for milvexian in SSP, adding that it continues to recommend investors buy shares ahead of the company's "series of high-profile, potentially high-reward" Phase 3 catalysts.

BofA

Buy

maintain

$64 -> $68

2026-02-06

New

Reason

BofA

Price Target

$64 -> $68

2026-02-06

New

maintain

Buy

Reason

BofA raised the firm's price target on Bristol Myers (BMY) to $68 from $64 and keeps a Buy rating on the shares. The firm raised near-term forecasts after the company delivered Q4 and FY26 guidance beats. Ultimately, Bristol Myers "is a pipeline story" and the firm thought Q4 commentary was supportive of some key programs where safety remains an open question, adding that read-across from competitor Bayer's (BAYRY) Phase 3 SSP results help to derisk that opportunity for milvexian.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMY

Unlock Now

BMY Should I Buy

BMY Should I Buy

Should You Buy Bristol-Myers Squibb Co (BMY) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch